DESTINY-CRC02: antibody-drug conjugates in colorectal cancer

Antibody Drug Conjugates for CancerПодробнее

Antibody–Drug Conjugates for Solid Tumors: Progress, Possibilities, and Implications for CareПодробнее

S1 Episode 4: Breakthroughs in HER2-Amplified Colorectal CancerПодробнее

Targeted Cancer Cell Killing with Antibody Drug ConjugatesПодробнее

Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid TumorsПодробнее

What are antibody-drug conjugates and how do they work against cancer?Подробнее

Antibody-drug conjugates in gynecological cancersПодробнее

Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology ConferenceПодробнее

BBC StoryWorks Rewriting Cancer Series | Targeting Cancer with Antibody-drug ConjugatesПодробнее

Understanding Antibody Drug ConjugatesПодробнее

Comparative Analysis of Anti-HER2 Antibody-Drug Conjugates in Tumor Spheroid ModelsПодробнее

Antibody-drug conjugates in the treatment of solid tumorsПодробнее

Antibody Drug ConjugatesПодробнее

Antibody-Drug Conjugates (ADCs): Current Research and Overcoming Challenges - Webinar PlaybackПодробнее

Answers to Key Questions About Antibody–Drug Conjugates in NSCLCПодробнее

Learning lessons from previous trials of ADCs in colorectal cancerПодробнее

Sanofi – Antibody – Drug ConjugatesПодробнее

Antibody drug conjugates in lung cancerПодробнее